CRISPLD2 Is a Target of Progesterone Receptor and Its Expression Is Decreased in Women with Endometriosis by Yoo, Jung-Yoon et al.
CRISPLD2 Is a Target of Progesterone Receptor and Its
Expression Is Decreased in Women with Endometriosis
Jung-Yoon Yoo1., Heesung Shin1,2., Tae Hoon Kim1, Won-Seok Choi3, Susan D. Ferguson1,
Asgerally T. Fazleabas1, Steven L. Young4, Bruce A. Lessey5, Un-Hwan Ha2*, Jae-Wook Jeong1*
1 Department of Obstetrics, Gynecology & Reproductive Biology, Michigan State University, College of Human Medicine, Grand Rapids, Michigan, United States of
America, 2 Department of Biotechnology and Bioinformatics, Korea University, Sejong, South Korea, 3 Department of Food Science and Technology, Korea National
University of Transportation, Chungbuk, South Korea, 4 Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina, United States
of America, 5 Department of Obstetrics and Gynecology, University Medical Group, Greenville Hospital System, Greenville, South Carolina, United States of America
Abstract
Endometriosis, defined as the presence of endometrial cells outside of the uterine cavity, is a major cause of infertility and
pelvic pain, afflicting more than 10% of reproductive age women. Endometriosis is a chronic inflammatory disease and
lipopolysaccharide promotes the proliferation and invasion of endometriotic stromal cells. Cysteine-rich secretory protein
LCCL domain-containing 2 (CRISPLD2) has high affinity for lipopolysaccharide and plays a critical role in defense against
endotoxin shock. However, the function of CRISPLD2 has not been studied in endometriosis and uterine biology. Herein, we
examined the expression of CRISPLD2 in endometrium from patients with and without endometriosis using
immunohistochemistry. The expression of CRISPLD2 was higher in the secretory phase in human menstrual cycle
compared to proliferative phase. The expression of CRISPLD2 was significantly decreased in the endometrium of women
with endometriosis in the early secretory phase compared to women without endometriosis. The increase of CRISPLD2
expression at the early secretory and dysregulation of its expression in endometriosis suggest progesterone (P4) regulation
of CRISPLD2. To investigate whether CRISPLD2 is regulated by P4, we examined the expression of the CRISPLD2 in the uteri
of wild-type and progesterone receptor knock out (PRKO) mice. The expression of CRISPLD2 was significantly increased after
P4 treatment in the wild-type mice. However, CRISPLD2 expression was significantly decreased in the (PRKO) mice treated
with P4. During early pregnancy, the expression of CRISPLD2 was increased in decidua of implantation and post-
implantation stages. CRISPLD2 levels were also increased in cultured human endometrial stromal cells during in vitro
decidualization. These results suggest that the CRISPLD2 is a target of the progesterone receptor and may play an important
role in pathogenesis of endometriosis.
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Introduction
Endometriosis is one of the most common causes of chronic
pelvic pain and infertility. It affects 10% of women of reproductive
age and the incidence increases to 35–50% in infertile women
[1,2]. The initiation of endometriosis is difficult to evaluate
because the disease has usually been prevalent for 8–11 years at
the time of clinical diagnosis [2,3]. Surgical removal of lesions and
hormonal suppression are the current gold standards of therapy,
but both approaches are associated with various side effects and a
high incidence of relapse. Endometriosis is a multifactorial disease
[4]. One of the major hallmarks of these uterine diseases is
disruption of steroid hormone control of uterine cell proliferation
and differentiation [5]. Elucidating the molecular mechanisms by
which the steroid hormones control uterine physiology is
paramount to understanding the pathology of these diseases.
The uterine endometrium is comprised of epithelial and stromal
compartments that undergo dynamic molecular and morpholog-
ical changes to allow for embryo implantation and development.
These changes are mediated by the ovarian steroids estrogen (E2)
and progesterone (P4). E2 stimulates proliferation of uterine
epithelial cells while P4 is inhibitory to E2-mediated proliferation
of the epithelium [6,7]. P4 achieves this inhibition of proliferation
through coordinating stromal-epithelial cross-talk. Disruption of
the steroidal control of uterine proliferation leads to the pathology
found in endometriosis. P4 exposure is a negative risk factor for
endometriosis [8], and pregnancy or progestin-based therapies can
lead to disease regression in some women [9,10]. However a
portion of patients with endometriosis and pelvic pain do not
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respond to treatment with progestins. Moreover, P4-induced
molecular changes in the eutopic (intrauterine) endometrial tissue
of women with endometriosis are either blunted or undetectable.
These in vivo observations are indicative of resistance to P4 action
in endometriosis [11]. Published microarray gene expression
profiles of the endometrium of women with or without endome-
triosis showed that a number of P4 target genes were dysregulated
during the window of implantation, at which time the endome-
trium is exposed to the highest levels of P4 [5,12]. Therefore,
understanding the role of the progesterone receptor and its target
genes is important for successful therapies in endometriosis
[13,14].
The cysteine-rich secretory protein LCCL (Limulus factor C,
cochlear protein Coch-5b2 and late gestation lung protein Lgl1)
domain-containing 2 (CRISPLD2) gene is a member of the
cysteine-rich secretory protein, antigen 5, and pathogenesis-related
1 proteins (CAP) protein superfamily and is 91 kb, located on
chromosome 16q24.1, and is consists of 15 exons [15]. It is
reported that CRISPLD2 is significantly associated with craniofa-
cial morphogenesis [16,17] as well as in alveolar development and
branching morphogenesis [18,19]. Crispld2 knockout (KO) mice
are embryonic lethal at 9.5 dpc. Heterozygous Crispld2 mice
display abnormal lung development with delayed alveolar
maturation [20]. Crispld2 plays a role in development or
differentiation in the lung and face [16–19]. Affinity of the LCCL
domains to lipid A of endotoxin such as lipopolysaccharide (LPS)
can block its interaction with host endotoxin receptors [21–23].
Therefore, CRISPLD2 was suggested as an anti-inflammatory
response gene [21].
During decidualization, P4-mediated differentiation is induced
along with an inflammatory response [13,24]. P4 normally
mediates the balance between anti-inflammatory and proinflam-
matory processes in uterus. However, progesterone resistance is
observed by alterations in progesterone responsive gene and
protein expression in women with endometriosis. Pelvic endome-
triosis lesions are thought to derive predominantly from retrograde
menstruation, which occurs in nearly all women [25,26]. A key
difference in women with endometriosis appears to be that
retrograde menstruation alters the inflammatory response and
immunosurveillance within the peritoneal fluid, facilitating prolif-
eration and recurrence of new disease [27]. In affected women,
inflammatory responses are seen both systemically and in eutopic
endometrium, which is populated by inflammatory leukocytes. It is
well recognized that chronic inflammation is associated with
endometriosis as with the majority of human diseases including
cancers [28]. Endometriosis is an estrogen dependent inflamma-
tory condition. However, the function of CRISPLD2 has not been
studied in endometrium and endometriosis. In the present study,
we investigated the expression level of CRISPLD2 in endometri-
um from patients with and without endometriosis. We also
explored the spatiotemporal expression and regulation of




The study has been approved by Institutional Review Com-
mittee of Michigan State University (Grand Rapids, MI), Green-
ville Health System (Greenville, SC) and University of North
Carolina (Chapel Hill, NC), and written informed consent was
obtained from all participants.
Human endometrium samples
The human endometrial samples were collected from the
Michigan State University’s Center for Women’s Health Research
Female Reproductive Tract Biorepository, the Greenville Hospital
System, and the University of North Carolina. For experiments
examining CRISPLD2 expression in endometrium throughout the
menstrual cycle, endometrium was obtained at the time of
laparoscopic surgery from 26 regularly cycling women between
the age of 18 and 50 undergoing hysterectomy for benign
indications (i.e. fibroids, prolapse). The presence or absence of
disease was confirmed during surgery. Women laparoscopically
negative for this disease were placed into the control group,
whereas women laparoscopically positive for this disease were
placed in the endometriosis group. Use of an IUD or hormonal
therapies in the 3 months preceding surgery was exclusionary for
this study. Histologic dating of endometrial samples was done
based on the criteria of Noyes [29] and confirmed by subsequent
histo-pathological examination by an experienced Fertility spe-
cialist (B.A.L.). To compare CRISPLD2 expression patterns of
endometrium from early secretory phase women with and without
endometriosis, 17 samples were collected from eutopic (n = 12) and
ectopic (n = 5) endometrium of women with endometriosis and 7
samples were from women without endometriosis.
Primary human endometrial stromal cell cultures and in
vitro decidualization
Human endometrial stromal cells (hESCs) were isolated from
endometrial tissue by collagenase digestion as previously described
[30,31]. hESCs were maintained in phenol red–free RPMI-1640
medium (Gibco, Grand Island, NY) containing 0.1 mM sodium
pyruvate (Gibco, Grand Island, NY), 10% fetal bovine serum
(FBS; Gibco, Grand Island, NY) depleted of steroids by pre-
treatment with dextran-coated charcoal (Sigma Aldrich, St. Louis,
MO) (Charcoal-stripped FBS; CS-FBS), and 1% penicillin
streptomycin (P/S; Gibco, Grand Island, NY). To induce in vitro
decidualization, hESCs were transferred to OPTI-MEM medium
(Gibco, Grand Island, NY) containing 2% CS-FBS, 10 nM
estradiol (E2, Sigma-Aldrich, St. Louis, MO), 1 mM medrox-
yprogesterone acetate (MPA; Sigma-Aldrich, St. Louis, MO),
50 mM cAMP (Sigma-Aldrich, St. Louis, MO), and 1% P/S.
Decidualization medium was changed every two days and
treatment lasted for 6 days. All results from in vitro decidualization
were confirmed in hESCs obtained from at least three indepen-
dent biological replicates.
Animals and tissue collection
Mice were cared for and used in the designated animal care
facility according to the Michigan State University institutional
guidelines. All animal procedures were approved by the Institu-
tional Animal Care and Use Committee of Michigan State
University. For the early pregnancy study, wild-type C57BL/6
mice at 8 weeks of age were mated with wild-type C57BL/6 male
mice and uterine samples from pregnant mice were obtained at
different days of pregnancy. The morning of vaginal plug
observation was designated as 0.5 days postcoitus (dpc) (n = 3).
For the study of steroid hormone regulation, wild-type and PRKO
mice [32] at 6 weeks of age were ovariectomized. Two weeks post-
surgery, ovariectomized mice were injected with vehicle (sesame
oil; Veh), progesterone (1 mg/mouse; P4), estradiol (0.1 mg/mouse;
E2), or E2 plus P4. Mice were euthanized at 6 hour after injection
(n = 3 per genotype per treatment). Uterine tissues were immedi-
ately frozen at the time of dissection and stored at 280uC for RNA
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extraction or fixed with 4% (v/v) paraformaldehyde for immuno-
histochemistry.
Quantitative real-time PCR
Total RNA was isolated using the RNeasy total RNA isolation
kit (Qiagen, Valencia, CA). The expression levels of CRISPLD2,
IGFBP1, and PRL mRNA were measured by real-time PCR SYBR
Green detection system (Bio-Rad, Hercules, CA) according to the
manufacturer’s instructions (PE Applied Biosystems, Foster City,
CA). mRNA quantities were normalized against the housekeeping
gene, 18S RNA. The sequences of the primers used for human
CRISPLD2 were 59-CGGACGAGATGAATGAGGTG-39 and 59-
TGACCGCAGAGGTT TTCTTG-39, mouse Crispld2 were 59-
CACCGAGAAAAGCCTCACAA-39 and 59-CTCGGCA TAT-
GCTGGAAGAA-39, for IGFBP1 were 59- CTATGATGGCTC-
GAAGGCTC-39 and 59-TTC TTGTTGCAGTTTGGCAG-39,
for PRL were 59- CATCAACAGCTGCCACACTT-39 and 59-C
GTTTGGTTTGCTCCTCAAT-39, and for 18S were 59- GT-
AACCCGTTGAACCCCATT-39 and 59- CCATCCAATCGG-
TAGTAGCG-39.
Immunohistochemistry
Uterine sections from paraffin-embedded tissue were cut at
6 mm and mounted on silane-coated slides, deparaffinized and
rehydrated in a graded alcohol series. Sections were preincubated
with 10% normal goat serum in PBS (pH 7.5) and then incubated
with primary antibody diluted in 10% normal goat serum in PBS
(pH 7.5) overnight at 4uC at 1:2000 dilution for CRISPLD2
(HPA030055; Sigma Aldrich, St. Louis, MO). On the following
day, sections were washed in PBS and incubated with 1:1000
diluted secondary anti-rabbit antibody (BA-1000; Vector Labora-
tories, Burlingame, CA) for one hour at room temperature.
Horseradish peroxidase conjugated streptavidin (SNN1004; Vec-
tor Laboratories, Burlingame, CA) at a dilution of 1:1000 was
added to the slides and incubated for 30 min. Immunoreactivity
was detected using DAB (SK-4100; Vector Laboratories, Burlin-
game, CA). Next, the nuclei were stained with hematoxylin
(Biocare Medical, Concord, CA) for 30 sec. The slides were
subsequently washed in water and increasing gradients of ethanol,
then placed in xylene before mounting in a xylene-based mounting
solution (Fisher Scientific Inc, Hanover park, IL). The immuno-
stained sections were observed under a microscope.
Western blot analysis
Cells were lysed using lysis buffer (10 mM Tris-HCl (pH 7.4),
150 mM NaCl, 2.5 mM EDTA, and 0.125% Nonidet P-40 (vol/
vol) in distilled water supplemented with both a protease inhibitor
cocktail (Roche, Indianapolis, IN) and a phosphatase inhibitor
cocktail (Sigma Aldrich, St. Louis, MO). Samples containing 30 mg
proteins were applied to 8% SDS-PAGE. The separated proteins
were transferred onto a polyvinylidene difluoride membrane
(Millipore Corp., Bedford, MA). Membranes were blocked for
two hours with 0.5% casein (wt/vol) in PBS with 0.1% Tween 20
(vol/vol) (Sigma Aldrich, St. Louis, MO) and probed with anti-
CRISPLD2 (HPA030055; Sigma Aldrich, St. Louis, MO)
antibody. Immunoreactivity was visualized by incubation with a
horse-radish peroxidase-linked second antibody and treated with
ECL reagents. To control for loading, the membrane was stripped,
probed with anti-Actin (sc1616; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA).
Statistical analysis
Statistical analyses were performed using one-way ANOVA
analysis followed by Tukey’s post hoc multiple range test using the
Instat package from GraphPad (GraphPad Software, Inc., San
Diego, CA). p,0.05 was considered statistically significant.
Results
Dysregulation of CRISPLD2 expression in endometrium
from women with endometriosis
Quantitative real-time PCR was conducted on endometrial
sections from endometrial biopsies to determine expression of
CRISPLD2 throughout the endometrium (Fig. 1A). CRISPLD2
mRNA was significantly increased in the secretory phase (n = 13)
as compared to proliferative phase (n = 5). We next used
immunohistochemical analysis to examine the cell-specific expres-
sion of CRISPLD2 in endometrium from proliferative phase
(n = 6) and early (n = 7), mid (n = 8), and late (n = 5) secretory
phase in women without endometriosis. CRISPLD2 protein
expression was significantly higher in endometrial stromal and
epithelial cells of the early and mid secretory phase as compared to
proliferative phase (Fig. 1B and C). Interestingly, we observed that
decidual cells have strong CRISPLD2 staining in late secretory
phase (Fig. 1B g and h). To determine if CRISPLD2 is
dysregulated in endometriosis, we examined the expression of
CRISPLD2 in endometrium from early secretory phase women
with and without endometriosis using immunohistochemistry. The
expression levels of CRISPLD2 was scored by measuring
expression intensity of early secretory phase women without
endometriosis (n = 7) and eutopic secretory phase endometrium
from women with endometriosis (n = 12). Interestingly, the protein
level of CRISPLD2 was significantly lower in the eutopic
endometrium obtained during the secretory phase from women
with endometriosis compared to cells from the control endome-
trium (Fig. 2). It has been shown that in women with
endometriosis, gene expression profiles in eutopic endometrium
and ectopic endometrium differs, and that alterations in gene
expression of the ectopic endometrium play an important role in
the pathogenesis of endometriosis. Therefore, we compared the
levels of CRISPLD2 protein in eutopic endometrium (n = 12) and
ectopic lesions (n = 5) from women with endometriosis.
CRISPLD2 protein was significantly higher in the epithelium of
ectopic lesions from women with endometriosis as compared to
eutopic endometrium (Fig. 3B). However, CRISPLD2 protein
expression was very weak in the stromal cells of ectopic lesions
(Fig. 3C).
CRISPLD2 expression in human endometrial stromal cells
(hESCs) during in vitro decidualization
P4 is a critical regulator of reproductive events associated with
endometrial stromal cell decidualization and maintenance of
pregnancy. Eutopic human ESCs from patients with endometriosis
showed an impaired decidualization [33,34]. To examine whether
CRISPLD2 is regulated during human endometrial stromal cell
differentiation, we used a well characterized in vitro model [31] to
induce decidualization in cultured human primary endometrial
stromal cells (hESCs) following treatment with estrogen, proges-
terone and cAMP. hESCs possess a fibroblast-like morphology.
After in vitro decidualization treatment, hESCs enlarged and
became round in shape, typical of the decidual transformation
(data not shown). Quantitative PCR analysis revealed significantly
increased expression levels of the decidualization marker genes
(IGFBP1and PRL) after treatment (Fig. 4A and B). Quantitative
PCR analysis and Western blot analysis were conducted on
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mRNA and proteins from control hESC or hormone-treated
hESCs on day 0, 1, 3, and 6 of in vitro decidualization. CRISPLD2
mRNA was significantly increased during in vitro decidualization
(Fig. 4C). Furthermore, non-secreted and secreted forms of
CRISPLD2 proteins were increased on day 1, 3, and 6 of in vitro
decidualization (Fig. 4D). These results suggest that CRISPLD2
plays an important role in the P4 regulation of human stromal cell
decidualization.
Crispld2 expression during early pregnancy in mice
To investigate the expression of Crispld2 during early pregnancy,
levels of Crispld2 were examined in uteri of C57BL/6 female mice
during early pregnancy. The initiation of pregnancy was marked
by the presence of the postcoital vaginal plug (0.5 dpc). As shown
in Fig. 5A, the expression of Crispld2 was detected on 0.5 dpc,
which gradually increased until 7.5 dpc, reaching statistical
significance after 2.5 dpc in the uterus. Interestingly, the
expression of Crispld2 was significantly decreased on 5.5 dpc
compared to 4.5 and 7.5 dpc. To further investigate the
spatiotemporal expression profile of CRISPLD2 protein in the
pregnant uterus, we performed immunohistochemistry during
sequential time points. The expression of CRISPLD2 was not
observed at 0.5 dpc. CRISPLD2 was highly expressed in the
glandular epithelium but at lower levels in the stromal cells at
3.5 dpc and strongly expressed in the epithelial and non-decidual
stromal cells at 4.5 dpc, the period during which the uterine
epithelium prepares for and permits the embryo to implant and
stromal cells are differentiated to decidual cells. The strong
expression of CRISPLD2 was disappeared at 5.5 dpc however,
CRISPLD2 was more detected in fully differentiated decidual cells
compared with primary differentiated decidual cells. Additionally,
CRISPLD2 was highly expressed in the secondary decidual zone
(further from the embryo) at 7.5 dpc than in the primary decidual
zone (closer to the embryo) (Fig. 5B). However, CRISPLD2 was
detected less after 9.5 dpc (data not shown). These results suggest
that CRISPLD2 have an important role for implantation and
decidualization during early pregnancy.
Figure 1. Comparison of CRISPLD2 expression in the endometrium during menstrual cycle. (A) Quantitative real-time PCR analysis of
CRISPLD2 gene expression in proliferative and secretory phase during the menstrual cycle normalized using the ddCt method to the 18S gene. The
results represent the mean 6 SEM. ** p,0.01. (B) Immunohistochemical analysis of CRISPLD2 in proliferative (a and b) and early (c and d), mid (e and
f), and late (g and h) secretory phase of the menstrual cycle. Black arrow head indicates a decidualized cell. (C) CRISPLD2 was scored by measuring
expression intensity of endometrial cells. The results represent the mean 6 SEM. * p,0.05.
doi:10.1371/journal.pone.0100481.g001
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Crispld2 is a progesterone and PR target gene in the
murine uterus
P4 regulates implantation, decidualization, and glandular
development via a complex paracrine signaling network [32,35–
37]. Endometriosis has been associated with a reduced response to
P4 in both the eutopic and ectopic endometrium. To determine
whether Crispld2 is a P4 and PR target gene, we performed real-
time PCR in the uterine samples of ovariectomized wild-type and
PRKO female mice treated with vehicle (sesame oil) or P4 for
6 hours. As shown in Fig. 6A, mRNA transcript of Crispld2 was
significantly increased in the uteri of P4 treated wild-type mice
compared to vehicle treated wild-type mice. To investigate
whether the P4 regulation of Crispld2 is relevant to PR, we
examined the expression of Crispld2 in the uteri of wild-type and
PRKO mice. After P4 treatment, induction of Crispld2 was not
detected in the PRKO mice (Fig. 6A).
To analyze the spatial expression of CRISPLD2 by P4 in the
uterus, we performed immunohistochemistry in the vehicle or P4-
treated wild-type and PRKO mice. Consistent with the real-time
PCR outcomes, we observed CRISPLD2 signal in the glandular
and luminal epithelium of the uterine section obtained from P4-
treated wild-type uterus (Fig. 6B). The CRISPLD2 signals were
not detected in the vehicle treated wild-type and vehicle or P4
treated PRKO uterine sections. These results indicate that
CRISPLD2 expression is regulated by P4 and PR in uterus.
E2 induces Crispld2 expression in the murine uterus
As endometriosis is an E2-dependent disease, E2 regulation of
CRISPLD2 was investigated. Ovariectomized female mice were
treated with vehicle (sesame oil), E2 (0.1 mg/mouse), or E2 plus
P4 (1 mg/mouse) for 6 hours. Our real time PCR results show
that Crispld2 mRNA expression was significantly increased in the
uteri of mice treated with E2 or E2+P4 as compared with vehicle.
Furthermore, immunohistochemical analysis that CRISPLD2 was
highly expressed in both luminal and glandular epithelial cells of
the uteri treated with E2 or E2+P4 for 6 hours as compared with
vehicle (Fig. 7). These results suggest that the expression of
CRISPLD2 was regulated by E2 as well as P4.
Discussion
PR is a major mediator of epithelial-stromal cross talk through
inhibition of the mitogenic effects of E2 and events leading to the
disruption of this communication can lead to P4 resistance in the
Figure 2. Comparison of CRISPLD2 expression in the endometrium between women with and without diagnosed endometriosis. (A)
Immunohistochemical analysis of CRISPLD2 in paired (a - d from women without diagnosed endometriosis; e - h from women with endometriosis)
endometrium. (B) CRISPLD2 was scored by measuring expression intensity of endometrial cells. The results represent the mean 6 SEM. * p,0.05
doi:10.1371/journal.pone.0100481.g002
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uterus [38–41]. P4 resistance is seen in a wide variety of diseases
including infertility, endometriosis, and endometrial carcinoma
[35,36,42]. Thus, the identification of P4-PR regulated genes is
crucial for understanding the causes of impairments in proper
uterine function. Herein, we show that expression of CRISPLD2 is
altered in the uterus of endometriosis patients, and CRISPLD2 is
consistently expressed during pregnancy via P4-PR signaling.
P4-PR signaling is critical during implantation, decidualization,
and glandular development. Crispld2 was identified as a P4 target
gene by using high density DNA microarray analysis [43].
However, the function of Crispld2 has not been studied in
endometriosis and uterine biology. Our results suggest that
Crispld2 is differentially expressed by the epithelial cells as well as
stromal cells of the murine uterus. During the pre-implantation
stage in mice, CRISPLD2 can only be detected in then glandular
epithelium. However, during implantation and post-implantation
stages, CRISPLD2 can also be observed in stromal cells and
decidual cells. These results suggest that CRISPLD2 may have an
important role in the uterine epithelium during pre-implantation
stage as well as for stromal cell decidualization at during the
implantation and post-implantation stages. Our results show that
the expression patterns of CRISPLD2 and PR/STAT3 are highly
correlated in decidual cells. These results suggest that CRISPLD2
may mediate PR/STAT3 function during decidualization.
Endometriosis is associated with aberrant gene expression in the
eutopic endometrium of women with disease. Aberrant gene
expression of critical factors such as aromatase, endometrial
bleeding factor, leukaemia-inhibitory factor, matrix metallopro-
teinases, and progesterone receptors, are dysregulated in the
endometrium of women with endometriosis [36,44–48]. Proges-
terone resistance is a hallmark of ectopic implants and plays a role
in endometrium dysfunction associated with the endometriosis
[2,11]. We observed that the expression level of CRISPLD2 was
significantly reduced in the endometrium from women with
endometriosis (Fig. 2). This result suggests that CRISPLD2 may be
involved in the pathogenesis or clinical sequelae of endometriosis.
CRISPLD2 was expressed largely in endometrial stromal cells,
and the expression was spatially and temporally regulated
throughout the menstrual cycle (Fig. 1). Furthermore, we analyzed
the expression pattern of CRISPLD2 during in vitro decidualiza-
tion using hESC [31]. The level of CRISPLD2 was remarkably
increased during decidualization process (Fig. 4 C and D). The
expression profile of CRISPLD2 suggests that this molecule plays
a role in decidualization. hESCs from patients with endometriosis
show impaired decidualization [34]. Additionally, PRKO mice
demonstrate a decidualization defect, suggesting that P4-PR
signaling has a critical role during decidualization [32]. Previous
studies have shown that P4 activates Indian Hedgehog (Ihh)
signaling to induce expression of chicken ovalbumin upstream
promoter transcription factor II (COUP-TFII) during decidualiza-
tion in endometrial stromal cells [49,50]. COUP-TFII has been
shown to promote stromal cell decidualization via induction of
bone morphogenetic protein 2 (BMP2) and inhibition of ERa
activation [49]. STAT3 and PR crosstalk is required for successful
embryo implantation and stromal cell decidualization in mice
[51,52]. Therefore, defining the specific role of CRISPLD2 would
be requisite to further understand dysregulation of PR signaling
pathways on etiology and infertility effect of endometriosis.
A key difference in women with endometriosis appears to be
that retrograde menstruation alters the inflammatory response and
immunosurveillance within the peritoneal fluid, facilitating prolif-
eration and recurrence of new disease [27,53,54]. In affected
women, maladaptive inflammatory responses are seen both
systemically and within the eutopic endometrium, which is
populated by inflammatory leukocytes. It is well recognized that
chronic inflammation is associated with endometriosis as well as
many other diseases. [28]. Endometriosis, however is a uniquely
estrogen dependent inflammatory condition, associated with
elevated tissue, peripheral and peritoneal cytokines levels [55].
An inflammatory survival cytokine required for decidualization,
STAT3 is known to interact with PR, a molecule required for
decidualization and known to interact with PR as well as the IL6
receptor in the uterus. Indeed, prolonged interaction with the IL6
causes [52,56,57]. In support of this inflammatory hypothesis,
many investigators have documented elevated IL6 levels in the
peritoneal fluid [58,59] and serum of women with endometriosis
[60,61]. P4 has recently been shown to mediates the balance
between anti-inflammatory and proinflammatory processes within
uterus [62,63] and P4 resistance is now becoming evident in a
wide variety of diseases, including endometriosis. Herein, we
showed that expression of CRISPLD2 was altered in the uterus of
endometriosis patients, and CRISPLD2 expression was regulated
by P4-PR signaling. Therefore, attenuation of an anti-inflamma-
tory response gene such as CRISPLD2 by progesterone resistance
may alter the innate immune system and play important
etiological role of endometriosis.
Figure 3. Comparison of CRISPLD2 expression in the endome-
trium between eutopic and ectopic endometriosis lesions. (A)
Representative immunohistochemistry of CRISPLD2 in eutopic and
ectopic endometrium with endometriosis. (B and C) CRISPLD2 was
scored by measuring expression intensity of endometrial epithelial (B)
and stromal (C) cells. The results represent the mean 6 SEM. *** p,
0.001; * p,0.05
doi:10.1371/journal.pone.0100481.g003
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We examined the expression profile of Crispld2 in mouse uteri
during early pregnancy to study the role of Crispld2 in female
reproduction. The expression of Crispld2 was gradually increased
until 7.5 dpc. It is highly expressed in the glandular epithelium but
at lower levels in the stromal cells at 3.5 dpc and then strongly
expressed in the epithelial and stromal cells at 4.5 dpc. These pre-
implantation time points are the period during which the uterine
epithelium prepares for and permits the embryo to implant,
suggesting that increased Crispld2 in the epithelium may play a
critical role in promoting implantation. CRISPLD2 was highly
expressed in secondary decidual zone at 7.5 dpc (Fig. 5). However,
CRISPLD2 was detected lower at 5.5 dpc than other stages. To
better understand the role of CRISPLD2 during early pregnancy,
the regulation mechanism of CRISPLD2 should be further
investigated. These results suggest that CRISPLD2 may have an
important role in epithelium at pre-implantation stage as well as
stromal cells for decidualization at implantation and post-
implantation stages.
We observed different expression patterns of CRISPLD2
between mice and women. The expression of CRISPLD2 was
strongly detected both stromal and epithelial cells in secretory
phase women. In mice, CRISPLD2 was detected in epithelial cells
at pre-implantation stage and ovariectomized mice, while stromal
cells were negative before decidualization occurs. The short
reproductive cycle length observed in rodents, (aka: estrous cycle),
makes them an ideal animal model for investigation of the
reproductive cycle. However, mice do not have the cyclic
spontaneous decidualization seen in humans. Therefore, we
examined the expression profiles of CRISPLD2 in murine uterus
during early pregnancy as well. CRISPLD2 is expressed by the
epithelial cells at pre-implantation stage in mouse, while it is not
detected at proliferative phase of human (a time of low P4 levels).
However, CRISPLD2 was strongly detected in decidual cells of
murine uterus (Fig. 5) as well as human endometrium from late
secretory phase women, a time of high P4 levels (Fig. 1).
Furthermore, CRISPLD2 increased during in vitro decidualization
of hESCs (Fig. 4). To further investigate the expression of
CRISPLD2 throughout pregnancy, we performed immunohisto-
chemical analysis on uteri of C57BL/6 female mice at 9.5, 11.5,
and 13.5 dpc. CRISPLD2 was only weakly expressed after 9.5 dpc
(data not shown). Surprisingly, CRISPLD2 was strongly expressed
in decidual cells of mouse as in human. These results suggest that
CRISPLD2 may play an important role for decidualization in
both mouse and human.
CRISPLD2 is a secreted glycoprotein with a conserved N-
terminal secretory signal peptide [64]. In our results, non-secreted
CRISPLD2 as well as secreted form were increased during in vitro
decidualization of hESCs (Fig. 4D). However, we were unable to
detect the secreted CRISPLD2 protein within the conditioned
medium of hESCs being decidualized in vitro (data not shown). The
ability of ovarian steroids to regulate uterine cell proliferation is
highly dependent upon the growth factor communication
networks linking the uterine stromal and epithelial cells. E2 is
known to stimulate proliferation in uterine epithelial cells while P4
inhibits this stimulation. P4 achieves this inhibition by coordinat-
ing stromal-epithelial cross-talk [37,65,66] but the precise mech-
anisms is still unclear. CRISPLD2 has previously been shown to
mediate distinct mesenchymal-epithelial signaling interactions in
early compared with late fetal lung organogenesis [64].
CRISPLD2 expression in the cellular compartments in this model
Figure 4. Expression of CRISPLD2 during in vitro decidualization of hESCs. (A to C) Expression of decidualization marker genes, IGFPB1 (A)
and PRL (B) and CRISPLD2 gene (C) were examined during in vitro decidualization of hESCs. The results represent the mean 6 SEM. * p,0.05; **, p,
0.01; ***, p,0.001. (D) Protein level of CRISPLD2 was measured by Western blot analysis. Actin was used as loading control. Black arrow head
indicates a non-secreted CRISPLD2 and white arrow head indicates secreted CRISPLD2.
doi:10.1371/journal.pone.0100481.g004
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is under tight temporal and endocrine control, similar to what we
see in the uterus. Of note, the mouse CRISPLD2 protein has 77%
similarity with the human amino acid sequence and 92% similarity
with rat, which may explain the differential expression patterns
seen in mouse vs human. Therefore, CRISPLD2 may mediate
stromal-epithelial cross-talk in the uterus. P4 is a crucial steroid
hormone in the female reproductive system associated with the
establishment and maintenance of pregnancy [40,41,67].
P4 regulation could be accomplished through progesterone
receptors (PRs). The PRs are constituted with two isoforms, PRA
and PRB, which are produced from the single gene containing
alternative translation initiation site. In 1995 and 1996, Lydon, et
al. investigated the P4-regulated pathways by using the mouse
Figure 5. The expression level of Crispld2 in pregnancy and the localization pattern of CRISPLD2 during early pregnancy. (A) The
expression level of Crispld2 was measured in uteri of early pregnancy. Total RNA used for the quantitative real-time PCR assays was prepared from
early pregnancy uteri. The results represent the mean 6 SEM of three independent RNA sets. * p,0.05; ** p,0.01; ***; p,0.001. (B) The localization
pattern of CRISPLD2 during natural pregnancy by immunohistochemistry were determined at 0.5 dpc (a and b), 2.5 dpc (c and d), 3.5 dpc (e and f),
4.5 dpc (g and h), 5.5 dpc (i and j), and 7.5 dpc (k and l). Black arrow head indicates embryo, PD means primary differentiated decidual cells, and SD
means secondary decidual zone.
doi:10.1371/journal.pone.0100481.g005
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model carrying a null mutation of the progesterone receptor
(PRKO) [32,68]. Previous studies demonstrated the essential roles
of P4-PR signaling for successful pregnancy [32,68]. Resistance of
P4-PR signaling triggers a variety of diseases in endometrium of
women such as infertility, endometriosis, and endometrial
carcinoma [35,36,42,69]. In our study, the expression level of
Crispld2 was significantly increased by P4 in wild-type mice, but
not in PRKO (Fig. 6). Both P4 and E2 are important for the
maintenance of the female reproductive system and implantation.
Especially, P4 is required throughout pregnancy. Embryo
implantation depends on hormone regulation and endometrial
status that are the proliferation of stromal cells and the
differentiation of these cells into a decidual phenotype to prepare
for blastocyst attachment. In mice in uterine sections of early
pregnancy, the CRISPLD2 expression is strong in the epithelial
cells of the pre-implantation uterus and then in decidual cells
following implantation. These results suggest that CRISPLD2 may
play an important during implantation and decidualization as a
PR target.
The binding of P4 to PR results in PR nuclear translocation and
subsequent alteration of P4 target gene transcription. Recently,
Rubel et al. identified uterine PR-regulated mechanisms and
downstream targets via chromatin immunoprecipitation followed
by deep sequencing (ChIP-Seq) [70]. This study provided an
important dataset for identification of target genes in the uterus
regulated by the P4-PR. These ChIP-Seq results showed that PR
directly binds to the proximal promoter region of Crispld2 gene in
the uteri of ovariectomized mice following treatment with P4.
Furthermore, our study herein has shown that CRISPLD2 was
significantly increased both epithelial and stromal compartments
of the human endometrium during the secretory phase as
compared to proliferative phase (Fig. 1), a time of elevated P4
levels and the onset of decidualization [71]. This further supports a
role for P4-PR in CRISPLD2 regulation in endometrium of both
Figure 6. The expression of CRISPLD2 in wild-type or PRKO mice. (A) The expression level of Crispld2 from P4 treated wild-type or PRKO uteri
by quantitative real-time PCR. Total RNA used for the quantitative real-time PCR was prepared from wild-type or PRKO uteri treated with P4 or vehicle
for 6 hours. The results represent the mean 6 SEM of three independent RNA sets. ** p,0.01; *** p,0.001. (B) The localization pattern of CRISPLD2
by immunohistochemistry in vehicle or P4-treated uteri. Uterine sections were collected from P4 or Veh treated wild-type (a and b) and PRKO (c and
d) mice for 6 hours.
doi:10.1371/journal.pone.0100481.g006
Figure 7. The expression of CRISPLD2 by steroid hormones. (A) The expression level of CRISPLD2 from vehicle, or estrogen (E2) treated uteri
by real-time PCR. Total RNA used for the real-time PCR assays was prepared from ovariectomized wild-type C57BL/6 mice treated with vehicle, E2, or
E2+P4 for 6 hours. The results represent the mean 6 SEM of three independent RNA sets. * p,0.5; ** p,0.01. (B) The localization pattern of CRISPLD2
by immunohistochemistry in vehicle, E2, or E2+P4 treated wild-type mice uteri for 6 hours. Nuclei were counterstained with hematoxylin.
doi:10.1371/journal.pone.0100481.g007
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mice and humans. Additionally, the expression of CRISPLD2 is
upregulated by glucocorticoid receptors on cultured airway
smooth muscle cells [72] and upregulated by retinoic acid in
myeloblastic leukemia cells (Gene Expression Omnibus (GEO)
database GDS1215). PR, glucocorticoid receptors, and retinoic
acid signaling pathways are relevant to uterine physiology and to
the pathogenesis of endometriosis. Although ligand binding elicits
distinct hormone-specific responses, PR and GR recognize
identical DNA response elements [73]. A question that continues
to engage the steroid receptor field is how these transcription
factors achieve DNA target specificity despite this degeneracy.
Therefore, the exact molecular mechanism of this regulation
requires further study.
In summary, this study observed that dysregulation of
CRISPLD2 in endometrium from women with endometriosis.
CRISPLD2 is highly expressed during decidualization in both
mouse and human. We determined that CRISPLD2 is a one of
target gene regulated by P4-PR response. These results suggest the
P4 regulation of CRISPLD2 may play an important role for
uterine function and pathology of endometriosis.
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